US Antidiabetics Drug Market Sales Revenue Clinical Trials Pipeline Report 2022

“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology (Prevalence of Type 1 and 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

Download Report:

https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"US Antidiabetics Drug Market Outlook 2022" Table of Contents

Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics

Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication

Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus

Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2

Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus

US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills

US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics

US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch

US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges

US Antidiabetics Drug Market Future Prospects

Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda

Figure 1-1: Illustration of the Categories of Diabetes Mellitus
Figure 1-2: Percentage of Different types of Antidiabetics Used
Figure 2-1: Historical Pathway of oral Diabetic Medication
Figure 3-1: Control of Glucose Uptake during Muscle Working
Figure 4-1: Categorization of Oral Antidiabetics Approved in US
Figure 4-2: Chemical Structure of Metformin, Phenformin and Buformin
Figure 4-3: Illustration of the Sub-Categories of Sulfonylureas
Figure 5-1: Mechanism of Insulin in Regulation of Blood Glucose Levels
Figure 5-2: Differences between Diabetes Mellitus 1 and 2 over Insulin
Figure 5-3: Structure of Differentiation of Peptidic Insulin Analogs
Figure 5-4: Demonstration of Action Profiles of Insulin Analogue
Figure 5-5: Activity Profiles of Different Types of Insulin
Figure 5-6: Difference between Lantus and Levemir
Figure 6-1: US: Number of Type 1 Diabetes Incidence (Million), 2016 and 2022
Figure 6-2: US: Number of Type 2 Diabetes Incidence (Million), 2014 - 2022
Figure 6-3: US: Type 1 Diabetes Prevalence Rate (%), 2016 and 2022
Figure 6-4: US: Type 2 Diabetes Prevalence Rate (%), 2014 - 2022
Figure 6-5: US: Diabetes Prevalence Rate among Adults Aged 18+ (%), 2010 - 2016
Figure 6-6: US: Obesity Rate Among Adults Aged 18+ (%), 2010 - 2016
Figure 6-7: US: Percentage of Adults with Obesity by State (%), 2015
Figure 6-8: Illustration of Total Cost of Diabetes Expenditure
Figure 6-9: Annual Average Cost Of Diabetes per Person in US
Figure 6-10: US: Productivity Loss Due To Type 1 Diabetes (US$ Billion), 2014 - 2022
Figure 6-11: US: Productivity Loss Due To Type 2 Diabetes (US$ Billion), 2014 - 2022
Figure 6-12: US: Medical Cost for Type 1 Diabetes (US$ Billion), 2014-2022
Figure 6-13: US: Medical Cost for Type 2 Diabetes (US$ Billion), 2014-2022
Figure 7-1: Overview of Diabetic Drug Market Segmentation
Figure 7-2: US: Antidiabetics Drug Market (US$ Billion), 2014 - 2022
Figure 7-3: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2016
Figure 7-4: US - Percentage of Most Common Class of Antidiabetics Drugs
Figure 7-5: US andndash; Percentage of Generally Prescribed Anti-Diabetic Drugs (%)
Figure 8-1: US - Insulin Degludec (Tresiba) Injection Sales (US$ Million), 2016-2022
Figure 8-2: US -Insulin Lispro Injection Sales (US$ Million), 2016-2022
Figure 8-3: US - Insulin Glargine (Toujeo) Injection Sales (US$ Million), 2016-2022
Figure 8-4: US - Insulin Glulisine (Apidra) Injection Sales (US$ Million), 2016-2022
Figure 8-5: US - Insulin Detemir (Levemir FlexTouch) Injection Sales (US$ Million), 2016-2022
Figure 9-1: Comparison of Price of Insulin Lantus and Basaglar
Figure 10-2: Estimated Insulin Basaglar Sales in Diabetes
Figure 10-1: Major Accelerative Parameters for Antidiabetic Market in US
Figure 10-2: Estimated Impact of Increasing Trend in Obesity by 2020
Figure 10-3: Estimated Increase in Total Number with Diagnosed Diabetes till 2050
Figure 10-4: Major challenges in Antidiabetics Market
Figure 10-5: Important Challenges with the Use of Insulin
Figure 11-1: US: Share of Antidiabetics Drug Market in Total Drug Market Spending (US$ Billion), 2022
Figure 11-2: Illustration of Antidiabetic Drugs Under Development

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.